WO1980002111A1 - Process and composition for treating disorders by administering lecithin - Google Patents

Process and composition for treating disorders by administering lecithin Download PDF

Info

Publication number
WO1980002111A1
WO1980002111A1 PCT/US1980/000342 US8000342W WO8002111A1 WO 1980002111 A1 WO1980002111 A1 WO 1980002111A1 US 8000342 W US8000342 W US 8000342W WO 8002111 A1 WO8002111 A1 WO 8002111A1
Authority
WO
WIPO (PCT)
Prior art keywords
lecithin
choline
brain
acetylcholine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1980/000342
Other languages
English (en)
French (fr)
Inventor
J Growdon
R Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of WO1980002111A1 publication Critical patent/WO1980002111A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Definitions

  • This invention relates to a process for the adminis ⁇ tration of lecithin in the absence of a drug in order to treat human disorders by increasing acetylcholine levels in brain and other tissues.
  • diseases which affect acetyl- choline-containing neurons in the brain or other tissues, and which are treated by drugs that cause undesired side effects by diminishing acetylcholine's release; there also exist diseases now treated by other drugs in which the potency and/or efficacy of the drugs could be improved by combining them with choline or natural or synthetic com ⁇ pounds that dissociate to form choline in order thereby to enhance the release of acetylcholine.
  • diseases include both those primarily involving the brain (e.g., diseases of higher cortical functions; psychiatric illnesses; move ⁇ ment disorders) and those involving the peripheral nervous system (e.g., neuromuscular disorders).
  • Tardive dys inesia is a particularly common movement disorder associated with inadequate release of brain acetylcholine as a result of drug administrations for the initial brain disease (e.g., phychosis) .
  • Tardive dyskinesia is a choreic movement dis ⁇ order characterized by involuntary twitches in the tongue, lips, jaw and extremities. It typically occurs in sus ⁇ ceptible persons after chronic ingestion of neuroleptic drugs and may involve an imbalance in the postulated recip ⁇ rocal relation between dopaminergic and cholinergic neurons in the basal ganglions.
  • catechola ine synthesis e.g., alpha-methyl-p-tyrosine5 , deplete the brain of monoamines (e.g., reserpine, tetra- benazine) or antagonize dopamine's actions on synaptic ' receptors (e.g., pherothiazines, galoperidol) often suppres tardive dyskinesia, whereas drugs that indirectly stimulate dopamine receptors (e.g., amphetamine, levodopa) often exacerbate the abnormal movements.
  • monoamines e.g., reserpine, tetra- benazine
  • antagonize dopamine's actions on synaptic ' receptors e.g., pherothiazines, galoperidol
  • drugs that indirectly stimulate dopamine receptors e.g., amphetamine, levodopa
  • Drugs assumed to increase the amount of acetylcholine within brain synapses e.g., physostigmine, deanol
  • acetylcholine also tend to suppress the chorea of tardive dyskinesia
  • anticholinergics e.g., scopolamine
  • choline administered by injection or by dietary supplementation increases blood choline levels in the rat; this, in turn, increases choline levels in cholinergic neurons within the brain and elsewhere in the body, thereby accelerating the synthesis of acetylcholine, increasing tissue acetylcholine levels, and increasing the amounts of acetylcholine released into brain synapses.
  • oral doses of choline or of lecithin, a naturally-occurring compound that dissociates to choline were found to cause dose-related increases in blood choline levels of sufficient magnitude (based on the studies on rats) to enhance brain acetylcholine synthesis and release; choline* levels in the cerebrospinal fluid also rose in parallel.
  • This invention is based upon the discovery that
  • lecithin when administered alone, optimizes physiological functions and restores impaired physiological functions in situations associated with inadequate cholinergi ⁇ trans ⁇ mission such as tardive dyskinesia, manic-depressive states or other psychiatric diseases, memory impairment, familial ataxias or the like.
  • the lecithin can be administered orally such as in tablet, capsule, granules or liquid form or parenterally by intravenous, intramuscular or sub ⁇ cutaneous injection.
  • lecithin is administered to a patient without a drug in order to in ⁇ crease blood levels of choline, and thereby to increase the level of acetylcholine in the brain.
  • the acetyl ⁇ choline is synthesized from choline and acetyl CoA in a reaction catalyzed by choline acetyltransterase (CAT) . It has been found that the administration of lecithin alone is useful for the treatment of physiological functions associated with inadequate cholinergic transmission.
  • the lecithin can be administered as lecithin with either saturated or unsaturated fatty acid side chains.
  • the lecithin is administered so that a choline level of at leas about 10-25 nanomoles/ml and usually between about 10 and 50 n moles/ml is attained in the patient's blood stream.
  • lecithin in a liquid carrier it is administered in amounts of between about 0.1 and 100 g/day.
  • lecithin is administered in granular form, as a tablet or in a capsule, it is- employed in amounts of between about 0.1 and 100 g/day, usually between about 30 and 50 g/day.
  • lecithin is not available as a pure compound and is available in admixture with other phospholipids wherein the lecithin comprises about 20-30 weight percent of the mixture.
  • a patient who was not taking medication, but who had suffered memory loss, but who did not suffer from any other brain dysfunction or from any psychiatric disease was treated with lecithin. Prior to the lecithin treatment, he was tested for memory quotient and intelligence quotient by the Wechsler Memory & Intelligence tests; his memory quotient was 122.
  • Lecithin obtained from the Nattermann Corporation and which comprises 80% lecithin was orally administered to the subject at a dosage of 109 every 8 hours over a period of 6 weeks.
  • the dosages were prepared by mixing the lecithin in foods.
  • Plasma samples for choline measurements were collected from the subject before the lecithin trial began and 6 weeks later during lecithin ingestion; plasma samples were separated, frozen and assayed for choline content by a con ⁇ ventional radioenzymatic method. Before treatment, plasma choline levels were 12.g + 1.1 nmol per milliliter. After lecithin ingestion, plasma choline levels in blood obtained 4 hours after a lecithin dose increased to 30.3 + 2.7 nmol per milliliter (P ⁇ .01). During the 6th week of lecithin ingestion at a time the plasma choline level was significantly elevated, his memory quotient improved to 140.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/US1980/000342 1979-04-05 1980-03-31 Process and composition for treating disorders by administering lecithin Ceased WO1980002111A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/027,209 US4221784A (en) 1979-04-05 1979-04-05 Process and composition for treating disorders by administering lecithin
US27209 1979-04-05

Publications (1)

Publication Number Publication Date
WO1980002111A1 true WO1980002111A1 (en) 1980-10-16

Family

ID=21836350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1980/000342 Ceased WO1980002111A1 (en) 1979-04-05 1980-03-31 Process and composition for treating disorders by administering lecithin

Country Status (4)

Country Link
US (1) US4221784A (cg-RX-API-DMAC7.html)
EP (1) EP0026223A1 (cg-RX-API-DMAC7.html)
JP (1) JPS56500374A (cg-RX-API-DMAC7.html)
WO (1) WO1980002111A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
EP0125900A1 (en) * 1983-05-16 1984-11-21 Massachusetts Institute Of Technology A pharmaceutical composition for use in treating neurological disease or aging

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
GB8331808D0 (en) * 1983-11-29 1984-01-04 Unilever Plc Food product
CH661438A5 (it) * 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US5135922A (en) * 1984-06-15 1992-08-04 Med-Tal, Inc. Prevention and treatment of microbial infection by phosphoglycerides
US5051410A (en) * 1988-09-01 1991-09-24 Massachusetts Institute Of Technology Method and composition for enhancing the release of neurotransmitters
US5001117A (en) * 1989-03-07 1991-03-19 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
DK1870103T3 (da) * 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
US7645795B2 (en) * 2004-09-21 2010-01-12 BodyBio, Inc Method for treating amyotrophic lateral sclerosis
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
BRPI0817387A2 (pt) * 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000924A1 (de) * 1977-08-30 1979-03-07 Hoechst Aktiengesellschaft Heterocyclische Phenyläther und Verfahren zu ihrer Herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2064727A (en) * 1931-05-02 1936-12-15 Buer Carl Heinz Process for the manufacture of stable preparations having a high content of commercial lecithin
US3088871A (en) * 1959-05-19 1963-05-07 Riker Laboratories Inc Process of stimulating the central nervous system
DE2004409A1 (de) * 1970-01-31 1971-09-02 Keimdiat GmbH, 8900 Augsburg Natürlicher Wirkstoff fur pharmazeuti sehe und diätetische Zwecke

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000924A1 (de) * 1977-08-30 1979-03-07 Hoechst Aktiengesellschaft Heterocyclische Phenyläther und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 88, 1978, Columbus, Ohio, USA, R.J. WURTMAN et al. "Lecithin consumpion raises scrum-free choline levels page 224, Abstract No. 60447 C pp. 68-9. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
EP0125900A1 (en) * 1983-05-16 1984-11-21 Massachusetts Institute Of Technology A pharmaceutical composition for use in treating neurological disease or aging

Also Published As

Publication number Publication date
JPS56500374A (cg-RX-API-DMAC7.html) 1981-03-26
US4221784A (en) 1980-09-09
EP0026223A1 (en) 1981-04-08

Similar Documents

Publication Publication Date Title
US4221784A (en) Process and composition for treating disorders by administering lecithin
US4351831A (en) Process and composition for treating disorders by administering isoxsurpine and choline
DE68912331T2 (de) Erniedrigung der zellvermehrung und steigerung der killerzellenaktivität.
CA1238280A (en) Pharmaceutical compositions containing bilobalid
DE2907778C2 (cg-RX-API-DMAC7.html)
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
US4636494A (en) Process and composition for treating disorders by administering amphetamine and choline
US20120329765A1 (en) Medicinal targeted local lipolysis
EP0552240A1 (en) New method of treating depression
US4609647A (en) Cytidyl diphosphocholine-drug composition and process
MC1552A1 (fr) Procede de fabrication de compositions anti-herpes synergiques
AU2004285264A1 (en) Medicamentously targeted local lipolysis
US4346085A (en) Process and composition for treating disorders by administering amphetamine and choline
US4569929A (en) Cytidyl diphosphocholine-drug composition
US4156013A (en) Method for treating patients suffering from anxiety neurosis and anxietylike neurosis, and alcoholism
EP0001924B2 (en) Pharmaceutical composition for administering choline
US4346084A (en) Process and composition for treating disorders by administering lithium and choline
US4355027A (en) Process and composition for treating disorders by administering piracetam and choline
US5407924A (en) Method of treating pain using inositol triphosphate
EP0217258B1 (en) The use of choline or choline releasing compounds for reducing the perception of fatigue
US4430330A (en) Process and composition for treating disorders by administering a phenothiazine and choline
US4456598A (en) Process and composition for treating disorders by administering a butyrophenone and a choline
EP0271023A2 (de) Verwendung von Dihydrophenylaminosäurederivaten und diese enthaltende Arzneimittel zur Immunmodulation und Cytostase
CN111514290B (zh) 一种葫芦素组合物及其用途
DE19650778A1 (de) Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP

AL Designated countries for regional patents

Designated state(s): GB